Pharmacogenomics enhance Value of Safety to Prescription Drugs: Toward a Post-genomics Era for Personalized Medicine and Patient Care

Abstract

Post-market surveillance is done with a much larger population, Abstract Despite numerous safety regulations and a robust methodology for the testing of pharmaceuticals before and after market entry, key safety issues, such as toxicity and side effects, represent some of the major health problems with the use of various pharmaceuticals. Presently, medical errors are at a bottleneck in health cost, a factor being drug errors in medicines if they cause intolerable or dangerous side effects. As our understanding of pharmacogenomics and genetics has increased its application in clinics and preventive medicine, we have come to understand that genetics and genomics play an important role, in not only how medications function for different variations in people, but also how metabolism variance responsible for causing symptomatic toxicology can be seen. In a post-genomics era, public health is moving towards preventive health care, such as reducing medical cost in various human diseases, and defining medical risks, including misuse or overuse of drugs pertaining to genetic polymorphisms that can cause disease initiation. This short review will discuss the prevalence of genetic variation in drug toxicity, will explore some current Omics-derived methodologies used to understand its application, and predict its responses due to drugs safety based on variable genetics spectrum in personal health care. More-over, it will make provisional guidance while consulting patient with drug complications due to its similarity versus genetic variance result in inconsistency of functional effectiveness Regarding the use of omics technologies and their application platform, it could be new avenue to improve pharmacological tolerance and reduce medical cost owing to complicated issues likely medical errors and